Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	99.42M 10.45M 9.03M 8.49M 7.72M 14.51M 1B 14.75M 38.87M 501M 39.25M 38.4M 1.66B	P/E 2026 *	-2.98x	P/E 2027 *	-2.48x
Enterprise Value	91.42M 9.61M 8.3M 7.8M 7.1M 13.34M 919M 13.56M 35.74M 460M 36.09M 35.31M 1.53B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	52.67%	Yield 2026 *	-	Yield 2027 *	-

08-13	Vivesto narrowed its loss in the second quarter, CEO says: we are staying on plan	FW
08-13	Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Calendar for Thursday, August 13	FW
07-07	Vivesto chairman Peter Zonabend increases his shareholding	FW
07-01	Vivesto Completes Enrollment in Cat Study of Paccal Vet	FW
07-01	Vivesto Completes Recruitment in Paccal Vet Dose-Finding Study in Cats and Determines Maximum Tolerated Dose	CI
06-26	Vivesto Completes Enrollment in Canine Study	FW
06-26	Vivesto Completes Recruitment in Paccal Vet Dog Pilot Study	CI
06-17	Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study	CI
06-16	Vivesto reports positive results for intravenous Cantrixil	FW
06-05	Sweden's Vivesto Names New Finance Chief	MT
06-05	Vivesto appoints Björn Svanström as new CFO	FW
06-05	Vivesto AB Announces Chief Financial Officer Changes	CI

05-26	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
11-21	DNB Carnegie Lowers Target Value for Vivesto Following Rights Issue Announcement	FW
13/08/25	DNB Carnegie Lowers Target Value for Vivesto as Costs Expected to Remain Steady	FW
09/07/24	Paccal Vet analysis could raise the temperature for Vivesto - Penser	FW
31/12/22	Orrön Energy the year's best and Isofol Medical the year's worst share on Nasdaq Stockholm	FW

08-14	Vivesto: Largely a non-event, key readouts ahead – Q2 review	AQ
07-01	Vivesto: Cat study enrolment completed, results expected in Q4	AQ
07-01	Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose	AQ
06-26	Vivesto: Paccal Vet top-line results expected in Q3	AQ
06-26	Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026	AQ

25/03/20	Oasmia Pharmaceutical AB (publ) : un partenariat stratégique pour la distribution d'Apealea
30/01/20	Oasmia Pharmaceutical AB (publ) : Apealea arrive sur les marchés scandinaves

Oasmia Pharmaceutical AB Stock NORDIC GROWTH MARKET

Stocks

OASM

SE0000722365

Pharmaceuticals

Valuation: Oasmia Pharmaceutical AB

Latest news : Oasmia Pharmaceutical AB

Last Transcript: Oasmia Pharmaceutical AB

Analysts' recommendations: Oasmia Pharmaceutical AB

Press Releases: Oasmia Pharmaceutical AB

News in other languages: Oasmia Pharmaceutical AB

Managers and Directors: Oasmia Pharmaceutical AB

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Erik Kinnman CEO	Chief Executive Officer	68	23/01/2023
Björn Svanström DFI	Director of Finance/CFO	55	01/07/2026
Teresa Fernandez Zafra CTO	Chief Tech/Sci/R&D Officer	39	01/01/2023

Director	Title	Age	Since
Isak Peter Zonabend CHM	Chairman	46	25/05/2022
Hege Hellstrom BRD	Director/Board Member	61	26/09/2019
Pål Ryfors BRD	Director/Board Member	43	25/05/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OASMIA PHARMACEUTICAL AB	-.--%	-.--%	-	-	10.45M
ELI LILLY AND COMPANY	-2.25%	-0.47%	+68.30%	+115.90%	1,052B
JOHNSON & JOHNSON	-0.66%	+0.43%	+47.39%	+50.54%	627B
ABBVIE INC.	-0.54%	+1.39%	+20.69%	+63.99%	441B
ROCHE HOLDING AG	-1.99%	-3.32%	+38.71%	+35.41%	349B
NOVARTIS AG	-1.05%	-2.81%	+23.07%	+35.70%	287B
ASTRAZENECA PLC	-2.12%	-3.67%	-1.14%	+5.37%	241B
AMGEN INC.	-0.63%	+1.04%	+40.05%	+56.09%	224B
NOVO NORDISK A/S	-1.19%	-3.41%	-9.57%	-52.71%	202B
GILEAD SCIENCES, INC.	+0.16%	+3.87%	+16.89%	+73.73%	172B
Average	-1.03%	+0.43%	+27.15%	+42.67%	399.46B
Weighted average by Cap.	-1.36%	+0.32%	+39.09%	+61.29%

	2026 *	2027 *
Net sales	-	-
Net income	-31M -3.26M -2.82M -2.65M -2.41M -4.52M -312M -4.6M -12.12M -156M -12.24M -11.97M -519M	-40M -4.21M -3.63M -3.41M -3.1M -5.84M -402M -5.93M -15.64M -201M -15.79M -15.45M -669M
Net Debt	-8M -841K -727K -683K -621K -1.17M -80.44M -1.19M -3.13M -40.28M -3.16M -3.09M -134M	-17M -1.79M -1.54M -1.45M -1.32M -2.48M -171M -2.52M -6.65M -85.6M -6.71M -6.57M -284M